Pfizer must face NYU in a lawsuit over royalties on a cancer drug, again
Once again, Pfizer will have to fend off claims by New York University that the drug maker owes “hundreds of millions of dollars” in royalties on a best-selling lung cancer treatment.
A New York state appeals court on Tuesday revived a four-year-old lawsuit in which the university maintains that Pfizer breached a long-standing contract and should pay 2.5 percent royalties on Xalkori, which racked up $561 million in sales last year. The New York State Supreme Court had dismissed the suit two years ago.
